BMY was trading up 3% in early trading, but is now down 2% because management disclosed on today’s CC that the CHMP rejected the MAA for Opdivo/Yervoy in first-line RCC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”